L3VLUP
ProSign in

TNDM · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TNDMJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TNDM
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterTNDMJNJ
Q3 202013 holders, $1.7bn30 holders, $26.2bn
Q4 20206 holders, $1.1bn32 holders, $26.6bn
Q1 20219 holders, $943m31 holders, $25.3bn
Q2 202110 holders, $1.1bn37 holders, $25.6bn
Q3 202113 holders, $1.5bn40 holders, $24.1bn
Q4 202116 holders, $1.9bn33 holders, $25.2bn
Q1 202213 holders, $1.4bn35 holders, $28.2bn
Q2 202210 holders, $740m33 holders, $26.9bn
Q3 20228 holders, $748m36 holders, $25.4bn
Q4 202211 holders, $836m35 holders, $27.6bn
Q1 202310 holders, $411m42 holders, $24.5bn
Q2 20239 holders, $306m38 holders, $25.0bn
Q3 20236 holders, $256m37 holders, $18.9bn
Q4 20238 holders, $388m31 holders, $19.0bn
Q1 20249 holders, $426m32 holders, $19.7bn
Q2 20247 holders, $332m35 holders, $20.4bn
Q3 20247 holders, $295m28 holders, $22.3bn
Q4 202410 holders, $188m37 holders, $20.4bn
Q1 20254 holders, $44m32 holders, $20.5bn
Q2 20257 holders, $74m31 holders, $18.4bn
Q3 20256 holders, $64m32 holders, $23.7bn
Q4 20255 holders, $81m29 holders, $27.8bn
Q1 20265 holders, $69m34 holders, $35.6bn
Q2 20266 holders, $73m33 holders, $39.1bn
TNDM

Tandem Diabetes Care Inc

Holders
5
Reported value
$81m
Buyers
13
Sellers
19

Breadth -6 among 92 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TNDM (3)

Baillie Gifford & Co, PDT Partners LLC, Winton Group Ltd

Only JNJ (27)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Rokos Capital Management LLP, Squarepoint Ops LLC, T. Rowe Price Associates Inc, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →